Colin Orford is a senior leader and experienced drug developer with 33 years of experience across GSK, Novartis, Quintiles, Eisai, and ICON. He combines scientific strategy with operational execution and is well-networked across biotech, pharma, and the pharmaceutical investment community. With 22 years of hands-on pharmaceutical development experience and 10 years leading ICON’s Drug Development team, Colin has spearheaded R&D project teams from preclinical through Phase IIIb, transitioning numerous molecules from candidate selection to late phase development. He has deep expertise in neurosciences, particularly in depression, anxiety, Alzheimer’s, and sleep disorders. Colin brings strong knowledge of regulatory guidelines for US, EU, and Japan markets, and expertise in due diligence for asset acquisition and investment funding. He has successfully guided Phase III teams through NDA and MAA submissions and works with emerging modalities such as cell and gene therapy.